Comprehensive Medical Weight Loss Denver
Get the latest developments in medical weight loss at Clinical Nutrition Center in Denver, Colorado, a doctor-supervised weight loss center. Ethan Lazarus, MD is a medical weight loss doctor helping patients achieve long-term weight control.
By Dr. Ethan Lazarus, MDBoard-Certified in Obesity Medicine and Family MedicineClinical Nutrition Center, Greenwood Village, CO Three state Medicaid programs have carved weight-loss medications out of coverage — and Colorado is on the list by default, not by design. Massachusetts…
Eight-five percent. That’s how many people stop taking their GLP-1 medication within two years. Not because the drugs stopped working. Not because they got lazy. Because the approach was wrong from the start. GLP-1 medications—Ozempic, Wegovy, Zepbound, Foundayo and their…
GLP-1 Medications and Cancer Risk: What a New Study Shows Published May 26, 2026 | Dr. Ethan Lazarus, MD A new study adds to a growing body of evidence that GLP-1 receptor agonists may do more than lower blood sugar…
A patient came in last month frustrated. She’d been on a GLP-1 medication for four months, had lost 18 pounds — and yet her body composition told a different story. She’d dropped muscle, not just fat. When I asked her…
For years, the standard answer was: eat less, move more. If that didn’t work, you didn’t try hard enough. We know better now. GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) work — in clinical trials, they work…
New Phase 3 Data: Survodutide Delivers 16.6% Weight Loss — Dual GLP-1/Glucagon Agonist Shows Metabolic Benefits Beyond the Scale The SYNCHRONIZE-1 Phase 3 trial results are in — and they’re worth your attention. Survodutide (BI 456906), Boehringer Ingelheim’s novel dual…
Amazon just entered the weight loss drug business. And if you’ve been watching the GLP-1 space, you probably saw it coming. On April 21, 2026, Amazon launched a GLP-1 Management Program through Amazon One Medical — combining virtual visits, prescription…
For years, the prevailing assumption was simple: GLP-1 drugs help the liver because they help you lose weight. Cut calories, shed pounds, your liver gets less fat, inflammation calms down. Thglp-1hanism seemed obvious. New research from Sinai Health in Toronto…
Not all GLP-1s are the same. And for the first time in this drug class, you actually have real choices. With orforglipron (Foundayo) now FDA-approved and oral Wegovy (25 mg semaglutide) newly available, patients and doctors face a genuinely useorforglipron:…
Let me start with a number that should get your attention: 28.7%. That’s how much body weight participants lost in the latest Phase 3 trial of retatrutide, Eli Lilly’s investigational triple-agonist obesity medication. At 68 weeks, the average weight loss…
